Haleon Selects Salesforce Agentforce Life Sciences Cloud to Enhance AI-Powered Healthcare Engagement

Haleon plc (LSE/NYSE: HLN), a global leader in consumer health, has partnered with Salesforce (NYSE: CRM) to enhance its engagement with pharmacies and healthcare professionals worldwide. The collaboration centers on deploying Salesforce’s Life Sciences Cloud for Customer Engagement, Data Cloud, and Agentforce to empower Haleon’s global sales team of over 4,500 employees. This AI-driven platform aims to improve efficiency, deepen relationships with healthcare providers, and ultimately increase access to essential daily health products for millions of consumers. Under the agreement, Haleon will leverage Salesforce’s advanced analytics and AI capabilities to gain data-driven insights into consumer demographics, purchasing behaviors, and point-of-sale marketing trends. This will allow sales representatives to shift focus from administrative tasks to higher-value activities such as designing customized business activation plans tailored to individual pharmacy needs. By streamlining workflows and enabling real-time decision-making, the solution is expected to significantly boost productivity and customer satisfaction. Notably, Haleon will serve as a design partner in the development of Salesforce’s Life Sciences Cloud for Customer Engagement. This collaboration will help shape future features to meet the specific demands of the consumer health sector, including support for global retail and e-commerce supply chains, product expiration management, promotional campaigns, and inventory tracking. Haleon’s firsthand experience with brands like Sensodyne, Voltaren, and Centrum positions it as a key contributor to refining tools that serve both large-scale and local healthcare stakeholders. Claire Dickson, Haleon’s Chief Digital and Technology Officer, expressed enthusiasm about the partnership, emphasizing that the new platform will enable pharmacists and healthcare professionals to deliver higher-quality, more personalized care. She also highlighted Haleon’s role in influencing the evolution of the platform, stating the company is committed to shaping the future of consumer health technology to support growth across all product categories. Frank Defesche, Salesforce’s General Manager for Life Sciences, praised Haleon’s adoption of the next-generation platform, noting it will redefine how consumer health companies interact with healthcare providers. He underscored that the solution meets complex industry needs without requiring custom development, while enhancing innovation, operational efficiency, and patient outcomes through real-time insights and trustworthy AI. The rollout of the platform is expected to accelerate Haleon’s digital transformation and strengthen its competitive edge in the global consumer health market. The partnership also reflects a broader trend in healthcare technology, where AI and data integration are becoming essential for improving service delivery and supply chain agility. Salesforce’s Life Sciences Cloud is set to include new order management functionality by October 2026, though this feature is still under development and subject to change. Customers are advised to base purchasing decisions on currently available capabilities. Haleon, with its portfolio of well-known brands including Advil, Centrum, Panadol, and Theraflu, remains dedicated to advancing everyday health through science, innovation, and human-centered solutions. The company’s mission is to make reliable health products more accessible worldwide. Salesforce, a pioneer in CRM and AI-driven enterprise platforms, continues to expand its footprint in healthcare, helping pharmaceutical and medical technology organizations achieve better health outcomes through intelligent automation and data integration. This partnership marks a significant step forward in leveraging technology to strengthen the connection between health brands and frontline healthcare providers, setting a new benchmark for digital engagement in the consumer health industry.